Poststroke hyperglycaemia (PSH) is common, has an unclear pathophysiology, and is associated with poor outcomes. Animal studies report conflicting findings. We systematically reviewed the effects of hyperglycaemia on infarct volume in middle cerebral artery occlusion (MCAO) models, generating weighted mean differences between groups using random effects models summarised as effect size (normalised to control group infarct volume as 100%) and 95% confidence interval. Of 72 relevant papers, 23 reported infarct volume. Studies involved 664 animals and 35 distinct comparisons. Hyperglycaemia was induced by either streptozotocin (STZ, 17 comparisons, n = 303) or dextrose (18 comparisons, n = 356). Hyperglycaemic animals had infarcts that were 94% larger, but STZ was associated with significantly greater increase in infarct volumes than dextrose infusion (140% larger versus 48% larger). In seven studies, insulin did not significantly reduce infarct size and results were heterogeneous. Although hyperglycaemia exacerbates infarct volume in MCAO models, studies are heterogeneous, and do not address the common clinical problem of PSH because they have used either the STZ model of type I diabetes or extremely high glucose loads. Insulin had a nonsignificant and significantly heterogeneous effect. Further studies with relevant models may inform clinical trial design.
Introduction
Poststroke hyperglycaemia (PSH) is common, with up to 68% of patients with acute stroke being documented as having a blood glucose concentration > 6.0 mmol/L at some point within 48 hours of stroke symptom onset (Fuentes et al, 2009; Matz et al, 2006; Scott et al, 1999; Yong and Kaste, 2008) . Hyperglycaemia in acute stroke is associated with a poor outcome (Baird et al, 2003; Bruno et al, 1999; Candelise et al, 1985; Capes et al, 2001; Fuentes et al, 2009; Weir et al, 1997; Yong and Kaste, 2008) , particularly in patients who have not been diagnosed with diabetes. Clinical intervention for PSH has a limited evidence base. The only large clinical trial of acute intervention to date, namely the GIST-UK (UK Glucose-Insulin Stroke Trial), found no significant benefit from insulin therapy started within 24 hours of stroke onset, but had a number of significant flaws that render interpretation difficult (Gray et al, 2007) . Clinical guidelines generally advise that blood glucose be monitored, and offer varied recommendations on thresholds for management or optimal treatment regimes. In addition to GIST-UK, a number of studies in other clinical scenarios have raised concerns about the safety of insulin treatment in acutely hyperglycaemic patients, primarily through a high incidence of hypoglycaemia (Finfer and Heritier, 2009; Griesdale et al, 2009) . Therefore, it is important to consider whether there is adequate evidence to support intervention in all patient groups before embarking on further large clinical trials. Important considerations include uncertainty about the importance of hyperglycaemia at different times after stroke onset, the balance of risk and benefit in intervention with insulin treatment, whether this differs according to the level of blood glucose, and whether the underlying insulin resistance states (including undiagnosed diabetes and more commonly impaired glucose tolerance) and 'stress' hyperglycaemia are equally important.
Understanding the pathophysiology of PSH in animal focal ischaemia models may inform clinical study design. However, studies have reported divergent results, e.g., some studies have reported that hyperglycaemia increases infarct growth, whereas others have suggested that high blood glucose may be beneficial (de Courten-Myers et al, 1988; Ginsberg et al, 1987; Kraft et al, 1990; Prado et al, 1988; Venables et al, 1985; Zasslow et al, 1989) . Few clinical studies have addressed pathophysiological processes associated with hyperglycaemia. The possible mechanistic explanations for the adverse effect of hyperglycaemia that have been advanced include higher intracranial bleeding risk after thrombolytic treatment and exacerbation of infarct growth resulting from reduced penumbral survival associated with lactic acidosis (Baird et al, 2003; Parsons et al, 2002; Wahlgren et al, 2008) .
We undertook a systematic review of the literature and meta-analysis primarily of studies of hyperglycaemia in animal models of focal ischaemia induced by middle cerebral occlusion (MCAO) and secondarily of the effect of insulin in these models. We aimed at clarifying the effect of hyperglycaemia on infarct volume in models of focal cerebral ischaemia and at elucidating the effect of insulin in such models. We hypothesised that clinically relevant concentrations of blood glucose would not have been widely used in animal studies and that the evidence for insulin affecting infarct volume would be inconsistent.
Materials and methods

Systematic Review
Studies of hyperglycaemia in animal models of MCAO were identified from Ovid Medline (1950 to March 2009 ) and Embase (1980 to March 2009 . The search strategy is specified in Supplementary Appendix 1.
Titles were screened for relevance, and abstracts for all potentially relevant papers were read by one investigator. We also performed hand searches of abstracts of scientific meetings including the 2008 World Stroke Conference, the 1981 to 2009 International Stroke Conferences, the 2005 to 2009 Brain Meetings, the 1992 to 2009 European Stroke Conference, and the Marburg Conferences from 1994 to 1998, and then screened reference lists of identified publications.
Inclusion Criteria
We included models of focal ischaemia induced by MCAO in which data were presented on infarct volume, defined either histologically or on brain imaging. The subset of papers that included data on the use of insulin, while meeting other inclusion criteria, was identified for additional analysis. We excluded models of global or forebrain ischaemia and studies, the data of which did not include volumetric data.
Data Extraction
We extracted data from the included papers on species, strain, gender, and weight of animals, model and timing of ischaemia, presence or absence of reperfusion, number of animals and experimental groups, experimental interventions, method of induction and timing of hyperglycaemia, level of hyperglycaemia, insulin use: timing of outcomes, as well as method of measuring infarct and mean final infarct size and s.d.
Studies that clearly reported the method of inducing hyperglycaemia and volume of final infarction with s.d. were included in further analyses.
If published data were incomplete, we contacted authors to obtain further information (Gisselsson et al, 1999; Kamada et al, 2007; Li et al, 1998c; Martin et al, 2006; Quast et al, 1995; Rizk et al, 2006; Zhang et al, 2003) .
Meta-Analysis
Data on infarct volume were recorded. To allow for different species in studies, the effect size was normalised to the mean of the control group (assumed 100%) before analysis in Review Manager 5.0.2 (Cochrane Collaboration; http://www.cochrane.org/) and Stats-Direct, version 2.7.3 (StatsDirect Ltd, Cheshire, UK) by means of a DerSimonian-Laird random effects model that expresses the difference between groups as a weighted mean difference for effect size and 95% confidence interval (95% CI). The significance of difference between groups was assessed by partitioning heterogeneity and using the w 2 distribution with nÀ1 degrees of freedom (d.f.), where n equals the number of groups.
Several stratified analyses were planned. We looked for a differential effect caused by either streptozotocin (STZ) or dextrose. The insulin studies were stratified by the control group (normoglycaemic or hyperglycaemic). We also compared permanent and transient MCAO models. To allow for multiple comparisons, we adjusted the significance level to P < 0.02 using the Bonferroni method.
Study Quality
We assessed the quality of the individual papers analysed in this study using a modified version of the CAMARADES (Collaborative Approach to Meta-Analysis and Review of Animal Data in Experimental Stroke) score (Macleod et al, 2004; Sena et al, 2007) , omitting a score for neuroprotective properties Hyperglycaemia and infarct size in animal models of MCAO NJJ MacDougall and KW Muir of anaesthetic agents used, and therefore giving a maximum score of 10 points.
Assessment of Bias
Funnel plots comparing s.e.m. treatment effect with effect size for each study were obtained and analysed by Egger's method to identify possible publication bias (Sterne and Egger, 2001) .
Results
Identification of Papers
The initial search produced 1,482 titles that were screened to identify 178 abstracts that were read in detail. From these abstracts, 57 papers were initially identified for data extraction. A further 15 papers were identified by hand searches. This is detailed in the flow chart shown in Figure 1 . A total of 22 papers reported data in a format suitable for meta-analysis (Araki et al, 1992; Berger and Hakim, 1989; Bomont and MacKenzie, 1995; Combs et al, 1990; de Courten-Myers et al, 1989 , 1994 Duverger and MacKenzie, 1988; Ginsberg et al, 1987; Huang et al, 1996; Kraft et al, 1990; Li et al, 2004; Liu et al, 2007; Nedergaard et al, 1986; Nedergaard, 1987; Quast et al, 1997; Slivka, 1991; Wei et al, 1997 Wei et al, , 2003 Wei and Quast, 1998; Zasslow et al, 1989) . One further paper was included when an author kindly contacted us with additional data for analysis (Martin et al, 2006) . Six papers had insufficient data to include in the meta-analysis (see Table 1 ). The remaining papers did not report infarct size, but included measurements of cerebral blood flow (Kawai et al, 1997; Nakai et al, 1988; Zhao et al, 1997) , brain biochemistry analysis (Marsh et al, 1986 ), blood-brain barrier function (Ennis and Keep, 2007) , genetic analysis, evaluation of tissue energy states (Chew et al, 1991; Folbergrova et al, 1992; , behavioural tests (Rejdak et al, 2001) , and immunohistochemical analysis.
From the 23 papers included, a total of 36 different comparisons of infarct size between hyperglycaemic and normoglycaemic controls after MCAO were described (see Table 2 ). These experiments used a total of 664 animals. In two cases, two comparisons used the same control group. This is noted below ( Table 2) . Hyperglycaemia was induced with dextrose infusion or injection in seven cat and one rabbit experiments. In rats, STZ was used in 18 comparisons, whereas dextrose infusion was used in 10. One study had useable data on infarct size but was excluded from analysis because it used a photosensitising model to induce local infarction instead of MCAO (Ginsberg et al, 1987) .
Streptozotocin was administered 48 hours before the experiment in 8 papers. In other studies, STZ was administered at earlier times (72 hours earlier in 2 studies, 4 days earlier in 1 study, 7 days earlier in 1 study, 5 to 6 weeks earlier in 3 studies, and 4 months earlier in 1 study; it must be noted that these numbers do not add up to 18 because some studies included more than 1 comparison group).
Dextrose infusions were started between 15 and 120 minutes (median time 30 minutes) before MCAO in comparisons in which hyperglycaemia was induced before occlusion. Dextrose infusion concentration varied from 10% to 50%. In comparisons in which hyperglycaemia was induced after MCAO, this was performed with an injection of 50% dextrose 5 to 20 minutes after ictus.
In nine papers, the frequency of monitoring of blood glucose was unclear. Glucose concentration was Hyperglycaemia and infarct size in animal models of MCAO NJJ MacDougall and KW Muir reported at the time of arterial occlusion and at an unstated time after occlusion in the remaining papers. Peak blood glucose values ranged from 18.4 to 31.2 mmol/L in hyperglycaemic groups and from 4.6 to 11.1 mmol/L in control groups. In the hyperglycaemic groups, the mean blood glucose was 23.9 mmol/L (95% CI: 22.4 to 25.3). In the control groups, the mean glucose was 8 mmol/L (95% CI: 7.3 to 8.7).
Study Quality
Study quality was generally low based on the modified CAMARADES score (median 3/10, range 1 to 6 points). All papers were published in peerreviewed journals. Blood pressure monitoring was documented in 20 of 24 papers, whereas temperature monitoring was documented in 22 of 24. Random allocation of animals to experimental groups was documented in only 6 of 24 papers, whereas blinded assessment of outcomes was only detailed in 7 of 24. No papers documented the blinded induction of ischaemia, sample size calculations, or a clear conflict of interest statement. The complete quality score table is included as Supplementary Appendix 2.
Assessment of Bias
Funnel plots (Figure 2 , Graphs A to C) suggested possible publication bias, with paucity of small, negative studies (particularly using the STZ model), but formal statistical analysis was not significant (Egger's bias test 2.88 (95% CI: À1.53 to 7.29, P = 0.1925)) (Sterne and Egger, 2001) .
Measurement of Effect Size
Infarct size was quantified by tissue staining (TTC (2,3,5-triphenyltetrazolium chloride) in 9 studies, cresyl violet in 4 studies, and haematoxylin and eosin in 11 studies) or by magnetic resonance imaging (MRI). Two histology studies used both cresyl violet and haematoxylin and eosin staining. One study reported only MRI measurement, and three others undertook both MRI and histology. In studies in which both techniques were used, we included MRI data as reported by the original authors. Infarct volume was measured at times ranging from 3 hours after arterial occlusion up to 2 weeks.
Streptozotocin Model and Dextrose Infusion Models
Hyperglycaemic animals had significantly larger infarcts (effect size 94, 95% CI: 69.1 to 118.9, P < 0.00001), but STZ was associated with greater exacerbation of infarct volume compared with dextrose alone (effect size 140.3, 95% CI: 104.8 to 175.9, P < 0.00001 versus 48.3, 95% CI: 14.8 to 81.9, P = 0.005) ( Figure 3 ). There was significant statistical heterogeneity between studies with w 2 = 1,208.7 with d.f. = 32 (P < 0.00001). There was also statistical difference between subgroups (w 2 = 186.3, d.f. = 1, P < 0.00001).
Permanent Versus Transient Middle Cerebral Artery Occlusion
The STZ model was associated with larger infarcts in both transient and permanent MCAO. In 9 comparisons involving 190 STZ-treated animals with permanent MCAO, the effect estimate for infarct size was 55.2 (95% CI: 31.2 to 79.1, P < 0.0001). There was statistically significant heterogeneity between studies (w 2 = 99.3, d.f. = 8, P < 0.00001). In 8 comparisons involving 115 STZ-treated animals with transient MCAO, the effect estimate for infarct size was 319.1 (95% CI: 191 to 447, P < 0.000001). There was statistically significant heterogeneity between studies (w 2 = 116.6, d.f. = 7, P < 0.00001). In 10 comparisons involving 227 dextrose-treated animals with permanent MCAO, the effect size was less than for STZ at 43.1 (95% CI: À0.05 to 86.2, P = 0.05) with statistically significant interstudy heterogeneity (w 2 = 509, d.f. = 9, P < 0.00001), and in 6 comparisons involving 140 animals with dextrose- 
Effects of Insulin Treatment
In comparing insulin treatment with either hyperglycaemic or normoglycaemic control groups, infarct volume was smaller with insulin, but not significantly so. Insulin did not significantly reduce infarct size (10 comparisons, n = 194, effect size À13.4, 95% CI: À41 to À5, P = 0.01), and results were heterogeneous in a statistically significant manner (w 2 = 54.8, d.f. = 7, P < 0.00001) (see Table 3 and Figure 4 ).
Discussion
Although a large body of clinical observational evidence indicates that hyperglycaemia in the acute phase of stroke is associated with poorer outcomes (Capes et al, 2001) , typically defined by death or dependence 90 days after the event, few clinical studies have addressed the mechanism by which this may occur (McCormick et al, 2010; Parsons et al, 2002) . Many mechanistic proposals are based on inferences drawn from animal models of focal ischaemia. In particular, the rationale for acute intervention to decrease blood glucose levels (usually by administration of insulin) is based on an assumption that the adverse effect of hyperglycaemia predominantly relates to exacerbation of acute infarct evolution. However, insulin treatment carries significant risks, particularly hypoglycaemia (Finfer and Heritier, 2009; Griesdale et al, 2009) , and the clinical evidence supporting an acute effect of hyperglycaemia is mainly observational and open to alternative interpretations. Data relating hyperglycaemia to early infarct volume can alternatively be explained by 'stress' hyperglycaemia resulting from more severe infarcts, for example. Recent observations that suggest that hyperglycaemia carries a higher risk of symptomatic intracerebral haemorrhage in patients treated with intravenous alteplase may be confounded by a similar effect (Bruno et al, 2002; Demchuk et al, 1999 ). An association of glucose concentration with lactate concentration in the infarct core and with infarct growth in a small observational study using MRI (Parsons et al, 2002) is mechanistically plausible, but without an intervention arm, could not discount the possibility that the relationship with blood glucose is not causal. In addition, the assumption that lactate itself is toxic in the ischaemic brain is not necessarily correct, with other evidence suggesting that lactate is instead produced as an alternative metabolic substrate and is beneficial (Berthet et al, 2009; Parsons et al, 2002) . Only one small clinical trial has attempted to address these mechanistic hypotheses using advanced imaging, and has found that insulin treatment reduced blood glucose and lactate concentration in the brain, but had no effect on infarct growth (McCormick et al, 2010) . Figure 2 Bias assessment plot for effect of hyperglycaemia on infarct size. Graph A is a bias assessment plot for all hyperglycaemic studies. Graph B is a bias assessment plot for studies using streptozotocin. Graph C is a bias assessment plot for studies using dextrose.
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Our systematic review yields findings that suggest that existing animal model data have limited relevance to the clinical situation, and that further studies may therefore be required to inform clinical study design.
First, although hyperglycaemia at the time of focal ischaemia onset increases infarct size, this is predominantly attributed to its large effect in the STZ rat model, which simulates type I diabetes mellitus (Like and Rossini, 1976) . Hyperglycaemia induced by dextrose infusion has a much smaller effect on infarct size, although still significant. Significant heterogeneity of effect size was present among both STZ and dextrose models. Although the animal data may be informative with regard to a biologic effect of hyperglycaemia on acute infarct volume, the clinical inferences that can be drawn are very limited. Dextrose infusion models typically administered hypertonic solution (20% to 50% dextrose) to yield blood glucose exceeding 20 mmol/L, a level considerably greater than is typically encountered in clinical practice (fewer than 2% of subjects in one study), and hence the clinical relevance of findings in this model system is unclear. Although only a minority of stroke patients have established diabetes mellitus (overwhelmingly type II diabetes), a high proportion of patients with acute hyperglycaemia after stroke are found to have unrecognised insulin resistance when followed (impaired glucose tolerance, metabolic syndrome, or undiagnosed type II diabetes) (Gray et al, 2004; McCormick and Muir, 2006) . No study of infarct volume used animals that model the insulin-resistant phenotype typical of patient populations.
The underlying mechanism for the difference in final infarct size between dextrose models and STZ models is uncertain. In models of global ischaemia, Figure 3 Meta-analysis of effect of hyperglycaemia on infarct size. d.f., degrees of freedom; 95% CI, 95% confidence interval.
Hyperglycaemia and infarct size in animal models of MCAO NJJ MacDougall and KW Muir the anatomic distribution and severity of brain damage in the STZ model is similar to that seen in animals acutely infused with dextrose (Li et al, 1998a) . It has been suggested that STZ may increase the rate of apoptosis in models of focal cerebral ischaemia (Britton et al, 2003) . The diabetic state induced by STZ may damage the microvasculature of the rat brain or impair the compensatory mechanisms that would normally protect from ischaemia. The difference in effect size raises a central question of whether the adverse effect arises from high glucose or from lack of insulin. The effect of insulin was nonsignificant, although the effect size estimate is consistent with reduction in infarct volume. However, as insulin may reduce infarct volume when compared with normoglycaemic control groups, it is possible that insulin does not act by reducing blood glucose in these model systems, and we cannot infer that reducing blood glucose (as opposed to administering insulin) represents an effective intervention. As the results of these studies are heterogeneous, a degree of caution is necessary when interpreting them.
To allow for comparisons involving different species and models, we used weighted mean differences in infarct volume normalised to the mean volume of the control group (Banwell et al, 2009; Wheble et al, 2008) . Given the small group sizes, and the possible exclusion of animals that either died or exhibited no evidence of infarction from group mean infarct volume measurements-commented on in only a handful of studies-the magnitude of effect size can be regarded only as an approximation.
Methodological quality of animal experiments is a significant concern because several reviews suggest that studies that do not report items such as blinding of outcomes and randomisation are more prone to bias than are more rigorous studies (Sena et al, 2007) . Quality scores have been based on criteria developed for preclinical evaluation of therapeutic interventions (e.g., the Stroke Therapy Academic Industry Roundtable [STAIR] criteria), which have gone through several iterations over time, rather than physiologic studies such as those predominantly reported herein. The median quality score using a slightly modified system used by the CAMARADES group (Macleod et al, 2004) was only 3 (out of a possible 10), and only 2 papers scored 6, which likely reflects a predominance of older papers and different standards of documentation for physiologic studies (e.g., items such as conflict of interest statements are not likely to be perceived as necessary, in contrast to drug treatment studies). The feasibility of blinding in some circumstances-such as STZ-pretreated animals and dextrose infusions in animals monitored by regular blood sampling-is also unclear.
We did not identify significant publication bias by a conventional analysis, but a recent publication has highlighted alternative methods such as 'trim-andfill' analysis (Sena et al, 2010) to estimate the effect of publication bias on efficacy outcomes in systematic reviews and meta-analysis of animal models of stroke (Duval and Tweedie, 2000) . This method estimates the number of unpublished studies that may exist based on the estimated proportion of unpublished data from the Egger regression. Although this approach suggested that up to onesixth of the studies were unpublished (with effect sizes potentially altered by one-third), the relevance of publication bias to physiologic studies rather than therapeutic agents is not established clearly. Even with an effect of this magnitude on overall estimates, hyperglycaemia would have a highly significant adverse effect on infarct volume.
In summary, although animal focal ischaemia models indicate exacerbation of infarct volume by acute hyperglycaemia, this effect reflects a particularly detrimental effect in a model of type 1 (insulin deficient) diabetes, with both a smaller effect size and considerable heterogeneity in acute hyperglycaemia induced by dextrose infusion, which may represent a situation analogous to 'stress hyperglycaemia'. No study has reported the effects of hyperglycaemia in an insulin-resistant model, which is potentially the most clinically relevant scenario. Few studies have investigated the effect of insulin on infarct volume, and as the concentrations of blood glucose induced in the model systems have generally greatly exceeded those relevant to clinical practice, we have no adequate data to support the current clinical guidelines suggesting intervention at concentrations X140 mg/dL (7.7 mmol/L) (Adams et al, 2007) .
